The Mergers + Acquisitions team advised AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) on the completion of the sale of its rights to Intrarosa® (prasterone) to Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group in 2018 that specializes in women’s health and menopause-related conditions, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million. AMAG has agreed to provide certain transitional services to Millicent Pharma for a limited period of time while Intrarosa® is operationally separated from AMAG.

AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas.

AMAG, Goodwin’s long-time public company client led by Stuart Cable and Jacqueline Mercier, was supported on this deal by an interdisciplinary deal team led by Robert Crawford and Mayan Katz, and which including Alexandra Haas (M&A); Robert Dzialo and Yasin Akbari (Corporate/ongoing); Janet Andolina (Tax); Julie Tibbets and Alexander Varond (FDA); Brian Mukherjee and Cecelia Lockner (R&W); Sarah Bock and Morgan Frisoli (Benefits); Jennifer Fay and Christina Bitter (Employment); Roger Cohen (Healthcare); Kirby Lewis (Antitrust); Nathan Brodeur (Environmental); Theresa Kavanaugh (IP); Deborah Birnbach and Adam Slutsky (Litigation); Barry Bazian (Restructuring); and with invaluable assistance from Sarah Solomon, Emily Beman, Martha Koroshetz and Katelyn Cidlevich.

For more details, please read the press release and additional coverage in Xconomy.